Mammogen Names National Cancer Screening Leader, Dr. Rebecca Kaltman, to Lead Pivotal genTRU-breast™ Study
20 October 2026
BioSpace | October 20, 2026
Mammogen announced the appointment of Rebecca D. Kaltman, M.D., Executive Director of the Inova Saville Cancer Screening and Prevention Center, as Principal Investigator for its KATELYN-ERIN clinical trial.
The study will evaluate genTRU-breast™, Mammogen's RNA-powered blood-based assay being developed to support earlier breast cancer detection, particularly for women with dense breast tissue.
Dr. Kaltman brings 20 years of experience in oncology, cancer prevention, and clinical research. Her leadership marks an important step as Mammogen advances its clinical validation efforts and explores how blood-based diagnostics can complement traditional breast imaging.

Mammogen announced the appointment of Robert S. Epstein, M.D., M.S., to its Board of Directors as an Independent Director. Dr. Epstein brings decades of experience in genomics, precision medicine, and oncology diagnostics, including leadership roles with Illumina, Veracyte, and Decipher Biosciences. His appointment strengthens Mammogen's leadership as the company continues advancing genTRU-breast™, its RNA-powered blood-based assay designed to support earlier breast cancer detection, through clinical validation and toward commercialization. Click Here to Read the Full Press Release →

Rockford News First | October 9, 2026 Rockford News First featured Mammogen CEO Elizabeth Cormier-May in a news segment discussing the growing role of blood-based testing in cancer detection. During the interview, Cormier-May explains how Mammogen is using RNA-powered technology to support earlier breast cancer detection, particularly for women with dense breast tissue. She also discusses how blood-based diagnostics could complement traditional mammography and help make cancer screening more accessible. Click Here to Watch the Full News Segment →

Will Payer-Dependent Diagnostics Companies Get Left Behind? Marty Keiser, Founder at IVBH / Mammogen
YouTube | Video Interview Mammogen founder Marty Keiser discusses the evolving diagnostics industry and the challenges facing companies that depend on insurance reimbursement and traditional payer models. The conversation explores the changing healthcare landscape and what these shifts could mean for diagnostics companies as they work to bring innovative technologies to market. Click Here to Watch the Full Interview →
